2.97
0.07 (2.41%)
| Previous Close | 2.90 |
| Open | 2.93 |
| Volume | 56,429 |
| Avg. Volume (3M) | 55,721 |
| Market Cap | 1,061,909,888 |
| Price / Earnings (Forward) | 59.88 |
| Price / Sales | 1.29 |
| Price / Book | 1.22 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -26.26% |
| Operating Margin (TTM) | -9.91% |
| Diluted EPS (TTM) | -0.690 |
| Quarterly Revenue Growth (YOY) | -4.20% |
| Total Debt/Equity (MRQ) | 52.48% |
| Current Ratio (MRQ) | 2.03 |
| Operating Cash Flow (TTM) | 34.59 M |
| Levered Free Cash Flow (TTM) | -90.11 M |
| Return on Assets (TTM) | -2.42% |
| Return on Equity (TTM) | -20.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Evotec SE | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -4.0 |
| Average | 0.50 |
|
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Institutions | 2.56% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Pitcairn Co | 30 Sep 2025 | 161,769 |
| Snowden Capital Advisors Llc | 30 Sep 2025 | 29,053 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Nov 2025 | Announcement | Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership |
| 05 Nov 2025 | Announcement | Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities |
| 04 Nov 2025 | Announcement | In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties |
| 29 Oct 2025 | Announcement | Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025 |
| 27 Oct 2025 | Announcement | Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |